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To the editor: In a recent issue of the Journal of Infection
and Chemotherapy, Miyashita et al. [1] reported on two
adult patients with pneumonia caused by macrolide-resis-
tant (mr) Mycoplasma pneumoniae. Concerning this, two
rather unexpected phenomena have been observed in
Japan, considering the prevalence of approximately 40% of
mr M. pneumoniae in pediatric patients in this country.
One phenomenon is that excessive morbidity, such as
frequent progression to respiratory failure, has not been
reported in association with mr M. pneumoniae infection.
Because the pathogenesis of M. pneumoniae pneumonia is
host immune mediated, it can be understood that the drug
resistance of M. pneumoniae in itself does not directly lead
to clinical severity. The other aspect is, as Miyashita et al.
argued, that mr M. pneumoniae pneumonia has seldom
been seen in adults in Japan. This author believes that these
two phenomena must be derived in common from some
unique biological characteristics of M. pneumoniae,a s
depicted in Fig. 1.
First, extrinsic genes such as plasmids do not function
within M. pneumoniae cells [2]. As a consequence, the
resistant mechanism of M. pneumoniae is exclusively a
point mutation in the domain V of 23S rRNA. Second,
M. pneumoniae has only one operon for constructing ribo-
somes [3]. As a consequence, drug-resistant strains of
M. pneumoniae that harbor a point mutation within their
rRNA genes are exclusively mutants of ribosomes. There-
fore, drug-resistant strains of M. pneumoniae must suffer
from less efﬁcient protein synthesis. Mycoplasma pneu-
moniae is fundamentally a fastidious, slowly growing
organism. Taking these points together, it can be speculated
that mr strains of M. pneumoniae in many instances must be
eradicated from the respiratory tract before propagating into
sufﬁcient amounts to develop pneumonia in adults, who are
far more active immunologically than children.
Bacteriostatic antimicrobial agents such as tetracyclines
have a disadvantage in that shedding of M. pneumoniae
persists for several weeks even after clinical recovery from
pneumonia. Therefore, patients treated with those drugs
can transmit the organism during that period. Mechanisms
of resistance to quinolones are point mutations, and wild-
type strains of quinolone-resistant M. pneumoniae must
emerge with high probability when these drugs are used far
more frequently than today to treat M. pneumoniae pneu-
monia. In conclusion, this author believes that there is no
urgent need to alter the concept that macrolides are the
ﬁrst-line drugs of choice for the treatment of M. pneumo-
niae pneumonia in adults as well as in children.
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Fig. 1 A diagram depicting two unexpected phenomena observed
in mr Mycoplasma pneumoniae infection with their possible mech-
anisms deduced from the unique biological characteristics of
M. pneumoniae
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